Zai Lab

Zai Lab Long-term Debt

Long-Term Debt of Zai Lab (ZLAB) as of Nov 22, 2026.

Long-term Debt

-USD

Last updated:

Long-Term Debt of Zai Lab is 2026 - USD. Long-Term Debt of Zai Lab was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

On Eulerpool you can find the complete historical development of Long-Term Debt Zai Lab since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Zai Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zai Lab

All Key Metrics — Zai Lab